Daily Derm Times: April 4, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Guselkumab Demonstrates Impact on Both Disease Progression and Symptoms in Psoriatic Arthritis

Tremfya is the first IL-23 inhibitor to significantly improve both symptoms and structural damage in active psoriatic arthritis.

The Power of Art in Clinical Spaces

Studies show that exposure to meaningful artwork can lower blood pressure and enhance mental clarity in patients.

Allergan Aesthetics' Effort to Create a Unified Vocabulary for Skin Quality

Sherket Peterson, PhD, spoke to Dermatology Times about Allergan’s recent research and plan to launch a universal skin quality index.

New Study Compares Infection Risk of AD Systemic Therapies

The study found dupilumab-treated patients had the highest probability of remaining infection-free over 52 weeks.

Patient Survey Highlights Dissatisfaction and Undertreatment in Hidradenitis Suppurativa Care

A cross-sectional survey revealed that many patients with HS are dissatisfied with treatment options, with gaps in knowledge about FDA-approved therapies.

Bridging the Communication Gap Between Providers and Patients Through the Skin Quality Index

Allergan’s latest initiative hopes to empower both patients and clinicians while advancing industry standards, according to Sherket Peterson, PhD.